A Novel PROTAC Confers a Dual Benefit Against Amyloid and Tau Pathology in Alzheimer's Disease via DAPK1 Degradation - PubMed

2 hours ago

A novel PROTAC named CP1 targets DAPK1 for degradation to address both amyloid and tau pathologies in Alzheimer's disease.
CP1 reduces Aβ generation and tau hyperphosphorylation in neurons and crosses the blood-brain barrier effectively in vivo.
In animal models, CP1 treatment lowered Aβ plaque burden, neuroinflammation, and improved cognitive functions in both amyloid and tauopathy models.
This approach shows potential as a disease-modifying therapy by tackling multiple upstream factors in Alzheimer's pathology.

Hasty Briefsbeta